First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting

由 Park, Keunchil, Lim, Darren Wan-Teck, Okamoto, Isamu, Yang, James Chih-Hsin
出版 2022